Adult onset Still's disease: experience from a tertiary care rheumatology unit
Article first published online: 20 OCT 2012
© 2012 The Authors International Journal of Rheumatic Diseases © 2012 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd
International Journal of Rheumatic Diseases
Volume 15, Issue 6, pages e136–e141, December 2012
How to Cite
Reddy Munagala, V. V., Misra, R., Agarwal, V., Lawrence, A. and Aggarwal, A. (2012), Adult onset Still's disease: experience from a tertiary care rheumatology unit. International Journal of Rheumatic Diseases, 15: e136–e141. doi: 10.1111/1756-185X.12012
- Issue published online: 18 DEC 2012
- Article first published online: 20 OCT 2012
- adult-onset Still's disease;
- DMARD ;
Adult-onset Still's disease (AOSD) is a rare chronic inflammatory disorder presenting with prolonged fever and polyarthritis.
Retrospective study of patients with AOSD, seen between 1992 and 2009 at a large tertiary care hospital.
Twenty-nine patients (18 female) with median age at onset of 28 (17–58) years were seen. The clinical features included fever in 29, inflammatory polyarthritis in 26, sore throat in eight and typical rash in 13. Lymphadenopathy was present in 15, hepatomegaly in 15, splenomegaly in 13 and serositis in five patients. Anemia was present in 22, neutrophilic leukocytosis in 28 and thrombocytosis in 13 patients. Acute phase reactants were elevated in all. Fifteen patients had transaminitis. Low titer antinuclear antibodies were present in 6/28 patients. On median follow-up (25 patients) of 23.7 months (range: 3–84) one patient had self-limited or monocyclic pattern, eight had polycyclic and 16 had chronic articular pattern. All patients received non-steroidal anti-inflammatory drugs and 25 received methotrexate and/or prednisolone. During the course 14 patients had remission and of these six were in remission on drugs at last follow-up. One patient received tociliziumab and was in clinical remission. One patient developed macrophage activation syndrome and one had atlanto-axial dislocation. Three patients developed tuberculosis and two died of infection associated with immunosuppression.
AOSD is an uncommon disorder with 1–2 patients seen at a large tertiary care rheumatology unit. Overall AOSD has a fair outcome with significant morbidity and most needing long-term therapy with steroids and methotrexate.